Apollo Ventures

Apollo Health Ventures is a transatlantic venture capital firm with offices in Berlin and Boston, focusing on biotechnology and health tech ventures aimed at extending human healthspan. Established in 2016, Apollo specializes in seed and early-stage investments, particularly in companies that target aging-related diseases and conditions. Their investments focus on developing technologies and therapeutics that address the root causes of aging, helping to maintain cellular health, reduce chronic inflammation, and strengthen the immune system. In 2021, Apollo closed its second fund at $180 million, supported by both existing and new investors. This fund is designed to build and invest in data-driven companies developing breakthrough treatments for age-related diseases. Apollo has co-founded several pioneering companies, including Samsara Therapeutics, which develops autophagy-enhancing molecules, and Aeovian Pharmaceuticals, which focuses on therapeutics to extend healthspan. The firm is led by a team of experienced biotech investors and entrepreneurs, including co-founder Nils Regge, whose ventures have raised over $1 billion in capital. The team also includes Dr. Jens Eckstein, a seasoned venture capitalist with a history of successful biotech investments, and Dr. Marianne Mertens, who brings extensive experience from life sciences and venture investing. With its unique focus on longevity and aging-related innovation, Apollo Health Ventures is at the forefront of biotech ventures aiming to transform healthcare.